dhh Antibody

What is DHH protein and why is it important in scientific research?

Desert Hedgehog (DHH) is a member of the highly conserved Hedgehog family of proteins involved in multiple developmental processes. DHH functions as a secreted signaling molecule that regulates cell growth and differentiation, playing crucial roles in embryonic development and tissue patterning through mediating cell-cell interactions . The protein is essential for proper organogenesis and maintenance of stem cell populations, making it a critical target for developmental biology research .

DHH is produced by Sertoli cells and is required for testis development and spermatogenesis. It induces steroidogenic factor 1, which is instrumental in promoting Leydig cell differentiation . DHH also promotes the deposition of basal lamina surrounding seminiferous tubules . In humans, mutations of DHH are associated with pure gonadal dysgenesis, highlighting its clinical relevance . Beyond reproductive biology, DHH is expressed by Schwann cells and is up-regulated following nerve injury, where it promotes the formation of the connective tissue sheath surrounding peripheral nerves .

What are the different types of DHH antibodies available for research applications?

Multiple types of DHH antibodies are available for various research applications, each with specific characteristics and advantages. These include:

• Mouse monoclonal antibodies: These offer high specificity for a single epitope. For example, DHH Antibody (F-9) is a mouse monoclonal IgG2a kappa light chain antibody that detects DHH protein from mouse, rat, and human origins .

• Rabbit polyclonal antibodies: These recognize multiple epitopes and can provide stronger signals in certain applications. For instance, the polyclonal DHH antibody (13889-1-AP) reacts with human, mouse, and rat samples .

These antibodies are available in various forms to suit different experimental needs:

The selection of the appropriate antibody depends on the specific research application, target species, and detection method preferred for the experiment .

What experimental applications are DHH antibodies validated for?

DHH antibodies have been validated for multiple experimental techniques, making them versatile tools for investigating DHH expression and function. According to the search results, DHH antibodies are validated for:

• Western Blotting (WB): For detecting DHH protein in tissue lysates, with recommended dilutions of 1:500-1:2000 for optimal results . DHH is typically observed at approximately 42 kDa on Western blots, though processed forms may appear at different molecular weights .

• Immunoprecipitation (IP): For isolating DHH protein complexes from cell or tissue lysates, allowing the study of protein-protein interactions .

• Immunofluorescence (IF): For visualizing the subcellular localization of DHH within cells and tissues, providing spatial information about protein distribution .

• Immunohistochemistry (IHC): For detecting DHH in tissue sections, revealing expression patterns in developmental studies or disease states .

• Enzyme-linked Immunosorbent Assay (ELISA): For quantitative detection of DHH in solution, allowing precise measurement of protein levels .

These diverse applications enable comprehensive investigation of DHH biology across different experimental contexts, from basic expression analysis to complex functional studies .

How is DHH protein processed post-translationally, and how does this affect antibody detection?

DHH protein undergoes complex post-translational processing that significantly impacts antibody detection strategies. DHH is initially synthesized as a 45 kDa precursor that undergoes several modifications before becoming functionally active . The protein contains a small N-terminal signal peptide that is cleaved intracellularly, generating a 39 kDa intermediate species .

Subsequently, DHH undergoes autocatalytic cleavage, resulting in:

• A 19 kDa N-terminal fragment that remains membrane-associated due to cholesterol and palmitate modifications

• A 25 kDa C-terminal fragment

These processing events create distinct challenges for antibody detection:

• Antibodies targeting different epitopes may recognize specific processed forms

• The observed molecular weight on Western blots may vary (typically observed at 42 kDa)

• Membrane-associated N-terminal fragments may require specialized extraction methods

• Secreted forms may require analysis of conditioned media rather than cell lysates

Researchers should consider these processing events when selecting antibodies and designing experiments to ensure detection of the relevant DHH forms for their specific research questions .

What are the recommended protocols for immunohistochemical detection of DHH in tissue samples?

Immunohistochemical detection of DHH requires careful consideration of several methodological aspects to obtain reliable and interpretable results. Based on the search results, here are key recommendations:

When performing immunohistochemistry with DHH antibodies, it's important to note that DHH is a highly secreted molecule, and staining does not necessarily imply the cell of origin . This characteristic must be considered when interpreting results, particularly in developmental studies.

DHH immunohistochemistry has been successfully applied to study expression patterns in tissues such as the tammar wallaby testis, where staining is most intense at the basal lamina during development and concentrates in developing spermatocytes in adult tissues . The staining typically appears as red/brown coloration, while hematoxylin counterstain (blue) helps visualize tissue architecture .

For optimal results:

• Use appropriately validated antibodies at optimized dilutions

• Include proper controls, particularly sections with the primary antibody omitted, to account for non-specific binding

• Consider co-staining for DHH receptors (PTCH1 and PTCH2) to gain insights into signaling dynamics, as these receptors show differential expression in different cell types (e.g., Sertoli cells vs. Leydig cells) and developmental stages

This approach allows researchers to correlate DHH expression with its biological functions in different tissue contexts and developmental stages .

How can researchers optimize Western blot protocols for DHH detection?

Optimizing Western blot protocols for DHH detection requires attention to several critical factors given the protein's complex processing and expression patterns. Based on the search results, here are key recommendations:

By carefully optimizing these parameters, researchers can achieve reliable and specific detection of DHH protein in Western blot experiments .

How do you distinguish between DHH and other hedgehog family proteins in experimental systems?

Distinguishing between DHH and other hedgehog family proteins (Sonic hedgehog/SHH and Indian hedgehog/IHH) presents a significant challenge due to structural similarities. Mouse DHH shares 74% amino acid sequence identity with mouse SHH and IHH , which can potentially lead to antibody cross-reactivity.

To achieve specific detection of DHH:

• Select antibodies with confirmed specificity. Some antibodies, such as the C-terminus specific antibodies, provide greater specificity. For example, mouse Desert Hedgehog/Dhh C-Terminus Antibody shows approximately 5% cross-reactivity with related proteins in direct ELISAs .

• Validate antibody specificity through:

  • Competitive blocking experiments with recombinant DHH protein

  • Parallel analysis of tissues with known expression patterns of different hedgehog family members

  • Genetic controls (DHH knockouts/knockdowns) when available

  • Correlation with mRNA expression data

• Consider complementary approaches:

  • Combine protein detection with transcript analysis (RT-PCR, RNA-seq)

  • Use multiple antibodies targeting different epitopes

  • Employ functional assays specific to DHH signaling

• When interpreting results, account for potential overlapping expression patterns of hedgehog family members in certain tissues and developmental stages.

This multi-faceted approach helps ensure that experimental findings genuinely reflect DHH-specific biology rather than general hedgehog signaling effects .

What are the key considerations when studying DHH expression in reproductive system development?

Studying DHH expression in reproductive system development requires careful experimental design and interpretation due to the protein's dynamic expression patterns and complex roles. DHH plays crucial roles in testis development and spermatogenesis, with several important considerations for researchers:

• Temporal dynamics: DHH expression changes throughout development, necessitating stage-specific analyses. In tammar wallaby studies, DHH expression patterns shift dramatically between developmental stages and adulthood .

• Cell-type specificity: DHH is produced by Sertoli cells but affects Leydig cell differentiation by inducing steroidogenic factor 1 . This intercellular signaling aspect requires methods that can capture both the source and target cells.

• Receptor expression: DHH interacts with both Patched (PTCH1) and Patched 2 (PTCH2) receptors, which show differential expression patterns. At early developmental stages (e.g., day D9pp in tammar wallaby), PTCH1 is present within Sertoli cells while PTCH2 predominates in Leydig cells. Interestingly, this expression profile reverses in adult testis, with PTCH1 found predominantly in Leydig cells and PTCH2 predominant in Sertoli cells .

• Secreted nature: DHH is highly secreted, and immunohistochemical staining does not necessarily indicate the cell of origin . Integration of protein localization with mRNA expression data can help identify producing cells.

• Functional consequences: DHH promotes the deposition of basal lamina surrounding seminiferous tubules, and mutations are associated with pure gonadal dysgenesis in humans . Correlating DHH expression with these structural and functional outcomes provides insight into its biological roles.

These considerations are essential for accurately interpreting DHH expression data in the context of reproductive system development and function .

How can DHH antibodies be utilized in cancer research studies?

DHH antibodies offer valuable tools for investigating abnormal hedgehog signaling in cancer, as aberrant activation of this pathway is implicated in various malignancies. The search results indicate that DHH upregulation in human ovarian cancer correlates positively with proliferative index and negatively with prognosis , highlighting its potential significance in cancer biology.

Researchers can utilize DHH antibodies in cancer studies through several approaches:

• Expression profiling: Immunohistochemical analysis of DHH expression in tumor samples can reveal upregulation compared to normal tissues. This approach helps identify cancers where hedgehog signaling may be driving tumor growth or progression.

• Prognostic marker evaluation: Correlating DHH expression levels with clinical outcomes can help determine its value as a prognostic biomarker, particularly in ovarian cancer where its expression correlates with proliferative index and prognosis .

• Signaling pathway analysis: DHH antibodies can be used to investigate the activation state of hedgehog signaling in tumor samples by examining both the ligand and downstream pathway components. This can identify patients who might benefit from hedgehog pathway inhibitors.

• Functional studies: Neutralizing antibodies against DHH can be employed in experimental models to block signaling and assess effects on cancer cell proliferation, invasion, and metastasis.

• Therapeutic target validation: DHH detection in patient samples can help stratify cases where anti-hedgehog therapies might be effective, particularly in cancers where aberrant hedgehog signaling drives tumor growth.

These applications highlight the dual utility of DHH antibodies in both basic cancer research and translational studies aimed at developing new diagnostic and therapeutic approaches .

How do recent advances in antibody design technologies impact DHH research?

Recent breakthroughs in antibody design technologies are revolutionizing research tools for studying proteins like DHH. According to the search results, significant advances have been made in "atomically accurate de novo design of single-domain antibodies" , which represents a paradigm shift from traditional antibody discovery methods.

• Epitope-specific targeting: Computational design enables the creation of antibodies that target specific functional domains of DHH with unprecedented precision. This allows researchers to study discrete regions of the protein and their specific functions in signaling.

• Improved specificity: De novo designed antibodies can be engineered to recognize DHH with minimal cross-reactivity to other hedgehog family members, addressing a major challenge in hedgehog research.

• Structure-function correlation: Recent work has demonstrated the generation of antibody variable heavy chains (VHHs) and single-chain variable fragments (scFvs) that bind user-specified epitopes with atomic-level precision . For DHH research, this could enable the development of antibodies that recognize specific conformational states of the protein.

• Affinity maturation: The search results describe approaches like OrthoRep that enable production of single-digit nanomolar binders that maintain intended epitope selectivity . This capability can produce high-affinity DHH antibodies for sensitive detection applications.

• Structural validation: Advanced structural biology methods like cryo-EM can confirm the proper Ig fold and binding pose of designed antibodies, verifying the atomically accurate conformations of CDR loops . This validation ensures the rational design approach yields functionally effective antibodies.

These advances enable researchers to develop increasingly sophisticated tools for studying DHH biology with unprecedented precision and specificity .

What role does DHH play in peripheral nerve development and injury, and how can antibodies help investigate these processes?

DHH plays significant roles in peripheral nerve development and regeneration, making it an important target for neuroscience research. According to the search results, DHH is expressed by Schwann cells and is upregulated following nerve injury . It induces the expression of Patched and Hip in nerve fibroblasts and promotes the formation of the connective tissue sheath surrounding peripheral nerves .

DHH antibodies can be invaluable tools for investigating these processes through several methodological approaches:

• Expression analysis: Tracking temporal and spatial changes in DHH expression following nerve injury using immunohistochemistry and Western blotting. This reveals the dynamic regulation of DHH during regenerative processes.

• Cell-specific localization: Co-immunostaining with cell type-specific markers can determine which cells express DHH during development and regeneration (e.g., Schwann cells) and which cells respond to DHH signaling.

• Functional studies: Neutralizing antibodies can block DHH signaling in experimental models to assess its role in nerve regeneration, potentially revealing therapeutic targets for enhancing recovery after nerve injury.

• Molecular pathway investigation: DHH antibodies can help elucidate the signaling cascades activated in response to nerve injury, particularly the interactions between Schwann cells and fibroblasts that contribute to nerve sheath formation.

• Translational research: DHH antibodies can be used to assess whether findings from animal models translate to human nerve pathology and regeneration processes.

These applications can provide valuable insights into the fundamental mechanisms of nerve development and repair, potentially leading to new therapeutic approaches for peripheral nerve injuries and neuropathies .

What are the current limitations of DHH antibodies and how might they be addressed in future research?

Current DHH antibodies face several limitations that affect their utility in certain research applications. Understanding these limitations and potential solutions is important for advancing DHH research:

• Cross-reactivity challenges: Due to the high sequence similarity between hedgehog family members (DHH shares 74% amino acid sequence identity with mouse IHH and SHH) , many antibodies may exhibit cross-reactivity. Future development of antibodies targeting unique regions or conformational epitopes specific to DHH could address this limitation.

• Detection of specific processed forms: DHH undergoes complex processing including autoproteolysis that generates N-terminal (19 kDa) and C-terminal (25 kDa) fragments . Many current antibodies may not distinguish between these forms. Epitope-specific antibodies designed to recognize specific processed forms could provide more detailed insights into DHH processing and function.

• Species limitations: While some antibodies recognize DHH across multiple species (mouse, rat, human) , there may be limited options for studying DHH in evolutionary or comparative biology contexts. Developing antibodies with broader species cross-reactivity would facilitate comparative studies.

• Functional blocking efficacy: Current neutralizing antibodies may have limited efficacy in completely blocking DHH signaling. The emerging technologies in atomically accurate antibody design could produce more effective blocking antibodies by targeting specific functional domains with higher precision.

• Quantitative limitations: Improved standardization of quantitative assays for DHH would enhance comparability between studies. Development of validated ELISA systems with recombinant standards could address this need.

• Live-cell imaging limitations: Current antibodies may have limited utility for live-cell tracking of DHH trafficking and signaling. Development of non-interfering antibody fragments or nanobodies compatible with live-cell imaging could overcome this limitation.

Addressing these limitations through continued technological innovation and validation will expand the research applications of DHH antibodies and deepen our understanding of DHH biology .

What are the optimal storage and handling conditions for DHH antibodies?

Proper storage and handling of DHH antibodies are crucial for maintaining their functionality and extending their usable lifespan. Based on the search results, here are the recommended practices:

Following these storage and handling guidelines will help ensure optimal antibody performance and reproducibility across experiments .

What controls should be included when working with DHH antibodies in different experimental systems?

Implementing appropriate controls is essential for ensuring the reliability and interpretability of experiments using DHH antibodies. Based on the search results and standard research practices, the following controls should be considered:

• Positive controls:

  • Tissues or cells with confirmed DHH expression (mouse skeletal muscle tissue is mentioned as a positive Western blot control)

  • Recombinant DHH protein for calibration in quantitative assays

  • Transfected cells overexpressing DHH for specificity verification

• Negative controls:

  • For immunohistochemistry, sections with the primary antibody omitted are specifically mentioned in the search results as important controls

  • Tissues known not to express DHH

  • Samples treated with DHH-specific siRNA or from DHH knockout models (when available)

• Specificity controls:

  • Competitive blocking with recombinant DHH protein

  • Analysis of cross-reactivity with other hedgehog family members (particularly important given the 74% sequence identity between DHH and other hedgehog proteins)

  • Use of multiple antibodies targeting different epitopes to confirm results

• Technical controls:

  • Loading controls for Western blotting (e.g., housekeeping proteins)

  • Internal staining controls for immunohistochemistry to evaluate tissue quality and fixation

  • Isotype controls matching the DHH antibody's host species and immunoglobulin class

• Application-specific controls:

  • For developmental studies, appropriate stage-matched controls

  • For comparative studies between normal and pathological samples, appropriate matched controls

How can researchers validate the specificity of DHH antibodies in their experimental systems?

Validating antibody specificity is crucial for ensuring reliable and reproducible research results, particularly for proteins like DHH that share high sequence homology with other family members. Here are comprehensive approaches to validate DHH antibody specificity:

• Multi-method validation:

  • Compare results across different applications (WB, IHC, IF, ELISA) to confirm consistent detection patterns

  • Correlate protein detection with mRNA expression using RT-PCR or RNA-seq

  • Verify results using multiple antibodies targeting different epitopes

• Molecular validation:

  • Use genetic approaches such as DHH knockdown/knockout systems to confirm signal reduction/elimination

  • Perform peptide competition assays with the immunizing peptide or recombinant DHH protein

  • Test for cross-reactivity with recombinant SHH and IHH proteins (particularly important given the 74% sequence homology)

• Technical validations:

  • Examine molecular weight consistency in Western blots (expected sizes: ~45 kDa precursor, 42 kDa typical detection, 19 kDa N-terminal and 25 kDa C-terminal fragments)

  • Verify the expected cellular/tissue distribution pattern (e.g., Sertoli cells in testes, Schwann cells in peripheral nerves)

  • Perform immunoprecipitation followed by mass spectrometry to confirm the identity of the detected protein

• Functional validation:

  • Correlate antibody detection with known biological functions of DHH

  • Use neutralizing antibodies and assess the impact on known DHH-dependent processes

• Documentation and reporting:

  • Maintain detailed records of validation experiments

  • Report the specific catalog number, lot number, and dilution used in publications

  • Include representative images of validation experiments in supplementary materials

These comprehensive validation approaches help ensure that experimental findings genuinely reflect DHH biology rather than artifacts or cross-reactivity with related proteins .